title: APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
abstract: The multifunctional HIV-1 accessory protein Vif counters the antiviral activities of APOBEC3G (A3G) and APOBEC3F (A3F), and some Vifs counter stable alleles of APOBEC3H (A3H). Studies in humanized mice have shown that HIV-1 lacking Vif expression is not viable. Here, we look at the relative contributions of the three APOBEC3s to viral extinction. Inoculation of bone marrow/liver/thymus (BLT) mice with CCR5-tropic HIV-1JRCSF(JRCSF) expressing a vif gene inactive for A3G but not A3F degradation activity (JRCSFvifH42/43D) displayed either no or delayed replication. JRCSF expressing a vif gene mutated to inactivate A3F degradation but not A3G degradation (JRCSFvifW79S) always replicated to high viral loads with variable delays. JRCSF with vif mutated to lack both A3G and A3F degradation activities (JRCSFvifH42/43DW79S) failed to replicate, mimicking JRCSF without Vif expression (JRCSFΔvif). JRCSF and JRCSFvifH42/43D, but not JRCSFvifW79S or JRCSFvifH42/43DW79S, degraded APOBEC3D. With one exception, JRCSFs expressing mutant Vifs that replicated acquired enforced vif mutations. These mutations partially restored A3G or A3F degradation activity and fully replaced JRCSFvifH42/43D or JRCSFvifW79S by 10 weeks. Surprisingly, induced mutations temporally lagged behind high levels of virus in blood. In the exceptional case, JRCSFvifH42/43D replicated after a prolonged delay with no mutations in vif but instead a V27I mutation in the RNase H coding sequence. JRCSFvifH42/43D infections exhibited massive GG/AG mutations in pol viral DNA, but in viral RNA, there were no fixed mutations in the Gag or reverse transcriptase coding sequence. A3H did not contribute to viral extinction but, in combination with A3F, could delay JRCSF replication. A3H was also found to hypermutate viral DNA.
  
  
  OBJECTIVE
  Vif degradation of A3G and A3F enhances viral fitness, as virus with even a partially restored capacity for degradation outgrows JRCSFvifH42/43D and JRCSFvifW79S. Unexpectedly, fixation of mutations that replaced H42/43D or W79S in viral RNA lagged behind the appearance of high viral loads. In one exceptional JRCSFvifH42/43D infection, vif was unchanged but replication proceeded after a long delay. These results suggest that Vif binds and inhibits the non-cytosine deaminase activities of intact A3G and intact A3F, allowing JRCSFvifH42/43D and JRCSFvifW79S to replicate with reduced fitness. Subsequently, enhanced Vif function is acquired by enforced mutations. In infected cells, JRCSFΔvif and JRCSFvifH42/43DW79S are exposed to active A3F and A3G and fail to replicate. JRCSFvifH42/43D Vif degrades A3F and, in some cases, overcomes A3G mutagenic activity to replicate. Vif may have evolved to inhibit A3F and A3G by stoichiometric binding and subsequently acquired the ability to target these proteins to proteasomes.
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: Krisko
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: Nurjahan
authors.initials: N
authors.lastname: Begum
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
authors.forename: Caroline E
authors.initials: CE
authors.lastname: Baker
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA victor_garcia@med.unc.edu john_foster@med.unc.edu.
authors.forename: John L
authors.initials: JL
authors.lastname: Foster
authors.affiliation: Division of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA victor_garcia@med.unc.edu john_foster@med.unc.edu.
authors.forename: J Victor
authors.initials: JV
authors.lastname: Garcia
mesh_terms: D000071480:APOBEC-3G Deaminase; D000483:Alleles; D000619:Aminohydrolases / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D003564:Cytidine Deaminase / Q000235:genetics / Q000378:metabolism*; D043525:Cytosine Deaminase / Q000235:genetics / Q000378:metabolism*; D004252:DNA Mutational Analysis; D004279:DNA, Viral; D004195:Disease Models, Animal; D005784:Gene Amplification; D015658:HIV Infections / Q000276:immunology / Q000378:metabolism* / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006239:Haplotypes; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009154:Mutation; D011485:Protein Binding; D059748:Proteolysis; D016415:Sequence Alignment; D019562:Viral Load; D014779:Virus Replication; D054320:vif Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
chemical_list: D004279:DNA, Viral; D054320:vif Gene Products, Human Immunodeficiency Virus; C514847:vif protein, Human immunodeficiency virus 1; C529313:APOBEC3H protein, human; D000619:Aminohydrolases; C492906:APOBEC3F protein, human; D043525:Cytosine Deaminase; D000071480:APOBEC-3G Deaminase; C464924:APOBEC3G protein, human; D003564:Cytidine Deaminase